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It is known that herpes simplex virus type 2 (HSV-2) triggers the activation of Toll-like
receptor (TLR) 9 signaling pathway and the consequent production of antiviral cytokines
in dendritic cells. However, the impact of HSV-2 infection on TLR9 expression and
signaling in genital epithelial cells, the primary HSV-2 targets, has yet to be determined.
In the current study, by using both human genital epithelial cell lines and primary genital
epithelial cells as models, we found that HSV-2 infection enhances TLR9 expression at
both mRNA and protein levels. Such enhancement is virus replication-dependent and
CpG-independent, while the HSV-2-mediated upregulation of TLR9 does not activate
TLR9 signaling pathway. Mechanistically, a SP1 binding site on TLR9 promoter appears
to be essential for HSV-2-induced TLR9 transactivation. Upon HSV-2 infection, SP1
translocates from the cytoplasm to the nucleus, and consequently binds to TLR9
promoter. By using specific inhibitors, the JNK signaling pathway is shown to be
involved in the HSV-2-induced TLR9 transactivation, while HSV-2 infection increases
the phosphorylation but not the total level of JNK. In agreement, antagonism of JNK
signaling pathway inhibits the HSV-2-induced SP1 nuclear translocation. Taken together,
our study demonstrates that HSV-2 infection of human genital epithelial cells promotes
TLR9 expression through SP1/JNK signaling pathway. Findings in this study provide
insights into HSV-2-host interactions and potential targets for immune intervention.
Keywords: herpes simplex virus type 2, toll-like receptor 9, genital epithelial cells, specificity protein 1, JNK
pathway
INTRODUCTION
Herpes simplex virus type 2 (HSV-2) is a large double-stranded DNA (dsDNA) virus that primarily
infects genital epithelial cells during the lytic cycle and can also eslishes a lifelong latency in
the sacral ganglia (1). HSV-2 infection causes clinical manifestations such as genital ulcers,
blindness and encephalitis (2, 3). HSV-2 is epidemiologically proven to enhance HIV-1 acquisition,
transmission and disease progression (4–6). An implication of HSV-2 to the pathogenesis of
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Kaposi’s sarcoma has also been proposed (7). To date, there
are still no preventative vaccines or curative measures available
against HSV-2.
During its infection and replication, HSV-2 can trigger
innate immunity through various recognition signaling pathways
including Toll-like receptor (TLR)-dependent and independent
pathways (8–10). TLRs are type I transmembrane proteins
that recognize pathogen-associated molecular patterns (PAMPs)
and signal via MyD88-dependent or TRIF-dependent pathways.
Different TLRs can recognize different HSV-2 components. For
instance, TLR2 recognizes glycoproteins gH/gL and gB (11),
TLR3 recognizes viral double-stranded RNA (dsRNA) (12) and
TLR9 recognizes unmethylated CpG motifs in viral dsDNA (13).
Activation of TLR-mediated signaling pathways leads to the
production of inflammatory cytokines.
Recognition of HSV-2 by TLRs, in particular TLR9, has
been reported by several studies. For instance, in plasmacytoid
dendritic cells (pDCs), both HSV-1 and HSV-2 can stimulate
IFN-α expression via TLR9/MyD88 signaling pathway, and
this stimulation is not viral replication-dependent (13). Certain
strains of HSV-1/2 are sequentially recognized by TLR2 and
TLR9 in conventional DCs (cDCs), but not pDCs, for the
induction of IL-6 and IL-12 (14). However, most of these
studies adopted immunocompetent cells like DCs as models,
and discrepancies have been observed (15). Given that HSV-2
predominantly infects epithelial cells at the portal of viral entry,
the findings obtained from DCs may not well represent the
events during its primary infection. In addition, previous studies
mainly focused on whether and how HSV-2 infection triggers the
activation of TLR9 signaling pathway, with little attention being
paid to the regulation of TLR9 expression.
In this study, by using human genital epithelial cell lines and
primary genital epithelial cells as models, we investigated the
impact of HSV-2 infection on TLR9 expression and signaling.
We demonstrated that HSV-2 upregulates TLR9 expression but
does not activate TLR9 signaling pathway. We further revealed
that HSV-2 enhances TLR9 expression in a viral replication-
dependent manner by promoting TLR9 promoter activation via
SP1/JNK signaling pathway.
MATERIALS AND METHODS
Cells, Virus, and Inhibitors
Vero cell line and human cervical epithelial cell linesME-180 and
HeLa were purchased from American Type Culture Collection
(ATCC) and cultured inDMEM supplemented with 10% FBS and
antibiotics. HSV-2 (G strain) was obtained from LGC standards,
propagated in ME-180, and titrated in Vero cells. Titrated
virus stocks were aliquoted and stored at −80◦C until use.
Signaling inhibitors specifically targeting TBK1/IKKε (BX795),
IκB-α (BAY11-7082), JNK (SP600125), and p38 (SB203580)
were purchased from InvivoGen and used according to the
manufacturer’s instructions.
Plasmids
Human TLR9 promoter sequence (−2,577/+77) was
amplified from genomic DNA and cloned into pGL3-Basic
luciferase reporter vector (Promega) and designated as
pGL3-TLR9. Truncations on TLR9 promoter were made
based on pGL3-TLR9, and designated as (−1,577/+77)TLR9,
(−1,077/+77)TLR9, (−577/+77)TLR9, (−377/+77)TLR9,
(−177/+77)TLR9, and (−77/+77)TLR9, respectively. Mutations
of transcription factor binding sequences on TLR9 promoter
were made based on full length pGL3-TLR9 using QuickChange
II Site-Directed Mutagenesis Kit (Agilent), and designated as
5′PU MUT, 3′PU MUT, 3′AP MUT, 5′AP+3′AP MUT, SP1
MUT and C/EBP MUT, respectively. Full open reading frames
of transcription factor specificity protein 1 (SP1) and TLR9
were amplified from human cDNA library and cloned into
pcDNA3.1(+) (Thermo Fisher Scientific) and designated as
pcDNA3.1-SP1 and pcDNA3.1-TLR9, respectively. The pRL-TK
Renilla luciferase control reporter vector was purchased from
Promega. All primers used for plasmid construction were listed
in Table S1.
Isolation and Infection of Primary Foreskin
Epithelial Cells
All protocols involving human subjects were reviewed and
approved by the Research Ethics Committee of Wuhan Institute
of Virology, Chinese Academy of Sciences. Informed written
consents from the human subjects were obtained in this study,
and informed written parental consents were obtained for all
participants under the age of 18.
Foreskin samples were obtained from teenagers who
underwent circumcision in Wuhan Medical and Healthcare
Center for Women and Children, and foreskin epithelial
cells were isolated as previously described (16). For infection
assay, cells were infected with HSV-2 at an MOI of 0.5
for 24 h. For signaling pathway inhibition, inhibitors
were introduced into the culture 1–2 h after infection
and maintained until 24 h. After 24 h of infection, cells
were lysed and TLR9 expression was determined by
Western blot.
HSV-2 Infection
Human cervical epithelial cell line ME-180 or primary foreskin
epithelial cells were preseeded in 24-well-plates 1 day before
infection. In most cases, cells were infected with HSV-2 at
an MOI of 0.5 for 24 h. For infection dose assay, cells
were infected with ascendant HSV-2 doses ranging from 0
to 2 MOI. For infection time course, cells were infected
with HSV-2 for ascendant time periods ranging from 0 to
30 h. UV-inactivated HSV-2 (UV-HSV-2) was obtained by
exposing viruses to UV irradiation for 15min as previously
described (17). To separate HSV-2 virus particles from cytokine-
containing medium, virus stocks were filtrated through a
100 kD ultracentrifugal filter tube (Thermo Fisher Scientific
Pierce) by centrifuging at 1,000 g for 20min at 4◦C. Filter-
through fraction (HSV-2 free cytokine fraction) was collected
directly while the membrane-retained fraction (cytokine-free
HSV-2 fraction) was diluted with fresh medium and collected
for infection.
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Transfection and Luciferase Reporter Gene
Assay
All plasmid transfections in this study were conducted using
Lipofectamine 2000 (Thermo Fisher Scientific Invitrogen)
according to the manufacturer’s instructions. For luciferase
reporter gene-based promoter activation, constructs carrying
promoter of interest in full-length, truncations or with mutations
were co-transfected with the Renilla-expressing control plasmid
pRL-TK into ME-180 cells. Four to six hours post transfection,
cells were infected with HSV-2 or UV-HSV-2 for another
24 h. Afterwards, cells were lysed and firefly luciferase and
Renilla luciferase activities were measured using the Dual
Luciferase Assay Kit (Promega) according to the manufacturer’s
instructions. For siRNA knockdown, siRNAs were transfected
24 h before plasmid transfection using X-tremeGENETM siRNA
Transfection Reagent (Roche) according to the manufacturer’s
instructions. For signaling pathway inhibition, signaling pathway
inhibitors were added 1–2 h after virus infection and maintained
until luciferase measurement. For CpG treatment, 4–6 h after
plasmid transfection, cells were treated with CpG (ODN 2395,
Miltenyi Biotec) or GpC (ODN 5328, Miltenyi Biotec) according
to the manufacturer’s instructions.
RNA Extraction and Semi-Quantitative
RT-PCR
Total RNA was extracted using RNeasy Mini Kit (Qiagen)
and then reverse-transcribed into cDNA using High-capacity
cDNA Reverse Transcription Kit (Thermo Fisher Scientific),
both according to the manufacturers’ instructions. TLR9 mRNA
level was semi-quantified by SYBR Green RT-PCR, as previously
described withmodifications (18). In brief, reaction was prepared
using SsoAdvancedTM Universal SYBR Green Supermix (Bio-
Rad) and PCR was run on a Bio-Rad CFX Connect platform.
GAPDH was used as an internal control and 2−11Ct was used
to calculate the relative expression of TLR9. The following
primer pairs were used. TLR9, forward: 5′-CGTCTTGAA
GGCCTGGTGTTGA-3′, reverse: 5′-CTGGAAGGCCTTGGT




IL-6 expression by ME-180 and peripheral blood mono-nuclear
cells (PBMCs) in response toHSV-2 infection or GpC stimulation
was quantified by ELISA. In brief, PBMCs were isolated from
single buffy coats of healthy donors obtained from NHS Blood
and Transplant using Histopaque (Sigma-Aldrich). ME-180 cells
with or without TLR9 overexpression and PBMCs were either
infected with HSV-2 or stimulated with CpG or control GpC
for 24 h. Cell culture supernatants were collected and IL-6 was
quantified by ELISA using human IL-6 ELISA kit (Thermo Fisher
Scientific) according to the manufacturer’s instructions.
Western Blot
For detection of protein expression at whole cell level, cell
lysates were prepared using Pierce IP Lysis buffer (Thermo Fisher
Scientific) supplemented with protease inhibitor cocktail (Roche)
and phosphatase inhibitor cocktail (Santa Cruz). For detection
of protein expression in cytoplasm and nucleus, cytoplasmic and
nuclear fractions were prepared using Pierce NE-PER Nuclear
and Cytoplasmic Extraction Kit (Thermo Fisher Scientific),
according to the manufacturer’s instructions. For Western blot
analysis, protein samples were first separated by 4–15% SDS-
PAGE gel (Bio-Rad), and then transferred onto a 0.45µm PVDF
membrane. After blocking with 5% non-fat milk, membrane
was incubated sequentially with primary and HRP-conjugated
secondary antibodies. Following the final incubation, membrane
was extensively washed, and immuno-bands were visualized
using ECL substrate (Millipore) under a CCD camera (LAS 4000,
Fujifilm). The following primary antibodies were used: mouse
anti-human TLR8 (Santa Cruz), rabbit anti-human TLR9 (Cell
Signaling Technology), mouse anti-human β-actin (Santa Cruz),
rabbit anti-human MyD88 (Cell Signaling Technology), mouse
anti-human SP1 (Santa Cruz), mouse anti-human HDAC1
(Santa Cruz), mouse anti-human JNK (Santa Cruz), rabbit anti-
human p-JNK (Cell Signaling Technology). The following HRP-
conjugated secondary antibodies were used: goat anti-mouse
IgG-HRP and goat anti-rabbit IgG-HRP (both from Abcam).
Chromatin Immunoprecipitation (ChIP)
Assay
ChIP was used to test the binding of SP1 to TLR9 promoter
using Piece Magnetic ChIP Kit (Thermo Fisher Scientific), as
previously described with modifications (19). In brief, cells
with or without HSV-2 infection were crosslinked with 1%
formaldehyde and harvested. Pelleted cells were then lysed and
digested with MNase in the presence of protease/phosphatase
inhibitors. After digestion, nuclear fraction was harvested, and
fragmentized chromatin was released from nuclei by sonication.
Immunoprecipitation was performed with a ChIP grade rabbit
anti-SP1 antibody (Merck Millipore) or a normal rabbit IgG
(negative control, Merck Millipore) overnight at 4◦C and pulled
downwith protein A/Gmagnetic beads. Recovered DNA samples
were used for PCR using TLR9 promoter specific primers.
Forward: 5′-AAGAGGAAGGGGTGAAGGAG-3′, reverse: 5′-
TTCCCACAGGGGCAGCAGCG-3′.
Statistical Analysis
All data in this study were expressed as mean ± standard
deviation (SD). Statistical analyses were performed with
GraphPad Prism 7.02. Mann–Whitney test was used for
comparison between two groups while Kruskal–Wallis test was
used when three or more groups were compared. For all
comparisons, a p< 0.05 was considered statistically significant.
RESULTS
HSV-2 Infection Increases TLR9
Transcription and Translation
It is known that HSV-2 activates several TLRs in pDCs (13).
Here we investigated the impact of HSV-2 infection on TLR7,
8, and 9 activation in human genital epithelial cells, the
main HSV-2 targets during primary infection. We constructed
luciferase-carrying plasmids under the control of TLR7, 8 or 9
promoter (named as pGL3-TLR7, pGL3-TLR8, and pGL3-TLR9,
respectively) and examined the responses to HSV-2 infection in
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cervical epithelial cells ME-180. As shown in Figure 1A, HSV-2
infection significantly induced TLR9 promoter activation. After
HSV-2 infection, TLR7 promoter was also moderately activated
but no apparent activation was observed for TLR8 promoter.
Since TLR9 promoter showed the highest level of activation upon
HSV-2 infection, we focused on HSV-2 infection-induced TLR9
upregulation. Western blot results showed that HSV-2-induced
activation of TLR9 promoter also led to the increase of TLR9
expression at protein level in both ME-180 (Figure 1B) and
primary foreskin epithelial cells (Figure 1C).
To exclude possible involvement of cytokines in the virus
stock, HSV-2 virus stock was filtered through a 100 kD
Amicon ultracentrifugal unit. Cytokine-free viruses and virus-
free supernatants were harvested separately and used to treat cells
transfected with pGL3-TLR9. Results showed that only virus-
containing fraction (cytokine-free HSV-2), but not HSV-2-free
cytokines induced TLR9 promoter activation, indicating that the
TLR9 induction was mediated by HSV-2 but not cytokines in the
samples (Figure 1D).
Further infection dose assay showed that TLR9 promoter
activation was enhanced when HSV-2 dose increased
(Figure 1E). Time-course assay revealed that HSV-2 induced
TLR9 promoter activation in an infection time-dependent
manner, which peaked around 24 h after infection (Figure 1F).
Consistent results were also observed at both mRNA and protein
levels (Figures 1G–J). In addition, ME-180 cells infected with 0.5
MOI of HSV-2 showed a much higher percentage of infection
compared to those infected with 0.1 MOI of HSV-2, which was
consistent with the levels of TLR9mRNA and protein, suggesting
that TLR9 expression was upregulated in HSV-2-infected cells
(Figures 1G,I and Figure S1).
Taken together, our data indicate that HSV-2 induces the
activation of TLR9 promoter and consequently leads to the
upregulation of TLR9 at both the mRNA and protein levels.
HSV-2-Induced TLR9 Upregulation Is Viral
Replication-Dependent
As a pattern recognition receptor, TLR9 is activated by
unmethylated CpG-rich DNA sequence and leads to the secretion
of pro-inflammatory cytokines. HSV-2, as a DNA virus, has
abundant CpG motifs in its genome. To assess if HSV-2-
induced TLR9 upregulation was a result of CpG-triggered
TLR9 activation, TLR9 induction by UV inactivated HSV-
2 and synthesized CpG ODNs was analyzed. As shown in
Figures 2A,D, only replicative HSV-2, but not UV-treated HSV-
2 or CpG ODN triggered the activation of TLR9 promoter.
Consistent results were observed at both mRNA and protein
levels (Figures 2B,C,E,F). These data indicate that HSV-2-
induced TLR9 upregulation is HSV-2 replication-dependent
and CpG-independent.
HSV-2 Induces TLR9 Expression Without
Activating TLR9 Signaling Pathway
Since HSV-2 infection induced TLR9 expression, we next
investigated whether this induction could activate TLR9
signaling pathway and cause the production of pro-inflammatory
cytokines like IL-6. We constructed a firefly luciferase reporter
plasmid under the control of IL-6 promoter and tested its
response to HSV-2 infection. Our data showed that HSV-2
infection induced the promoter activation of TLR9 but not that
of IL-6 (Figure 3A). To further confirm these results, we treated
ME-180 cells with HSV-2 or CpG ODNs and measured the IL-
6 concentration in the supernatants. As shown in Figure 3B,
neither HSV-2 infection nor CpG treatment induced IL-6
expression. As a positive control, CpG treatment significantly
increased IL-6 in the PBMCs (Figure 3B). Upon activation,
TLR9 binds to its adaptor protein MyD88, which subsequently
activates downstream signaling pathway. To assess if HSV-2
infection-upregulated TLR9 was activated and able to bind to
MyD88, co-immunoprecipitation with anti-MyD88 antibodywas
performed. As shown in Figure 3C, no interaction between HSV-
2-upregulated TLR9 and MyD88 was detected. However, TLR9
overexpression by transfection with pTLR9 plasmid showed
binding of the two proteins. In consistent, pTLR9 transfection
alone also triggered high level of IL-6 expression (Figure S2).
Taken together, these data indicate that HSV-2 infection induces
TLR9 expression without activating the TLR9 signaling pathway.
SP1-Binding Site in TLR9 Promoter Is
Involved in HSV-2-Induced TLR9
Expression
Since TLR9 promoter could be transactivated by HSV-2
infection, we next investigated whether one or more cis-elements
in the TLR9 promoter was involved in this transactivation. 5’
serial truncations of TLR9 promoter showed that HSV-2 induced
luciferase activity was lost when−177 to−77 bp of the promoter
were deleted (Figure 4A). Additional bioinformatics analysis
predicted a few transcription factor binding sites in this region,
including PU box, AP1, SP1, and C/EBP (Figure 4B). Removal
of these sites by point-direct mutations showed that only the
mutation of the SP1 binding site demolished the responsiveness
of TLR9 promoter to HSV-2 infection, indicating that the SP1
binding site within−177 to−77 bp is essential for the HSV-2-
induced TLR9 promoter activation (Figure 4C).
SP1 Binds to TLR9 Promoter After HSV-2
Infection
Given the importance of SP1 binding site in TLR9 transactivation
upon HSV-2 infection, we proposed that HSV-2 infection
likely activates TLR9 promoter by promoting SP1 binding to
SP1 binding site in the promoter. To test this hypothesis,
ChIP assay was performed and TLR9 promoter fragment
containing the SP1 binding site was amplified by PCR. As
shown in Figure 5A, a positive amplification of the fragment
was only seen in the pulldown by anti-SP1 antibody in
HSV-2 treated cells, but not by control IgG or in cells
without HSV-2 treatment. This indicates that HSV-2 infection
enhances TLR9 expression through promoting SP1 binding to
TLR9 promoter.
To further confirm the role of SP1 on TLR9 promoter
transactivation, the activation level of TLR9 promoter was
measured under the condition of SP1 overexpression. As
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FIGURE 1 | HSV-2 infection induces TLR9 expression in genital epithelial cells. (A) ME-180 cells were transfected with reporter plasmid pGL3-TLR7, pGL3-TLR8 or
pGL3-TLR9 and infected with or without HSV-2. Twenty-four hours later, relative luciferase activity was measured. Data shown are mean ± SD of three independent
experiments with each condition performed in duplicate. (B,C) ME-180 (B) and primary foreskin epithelial cells (C) were infected with HSV-2 for 24 h and the
expression of TLR8 and TLR9 was determined by Western blot. One representative experiment out of three is shown. (D) HSV-2 stock was fractionized into
cytokine-free viruses and virus-free cytokines by ultrcentrifugation and both fractions were used to infect ME-180 cells transfected with pGL3-TLR9. Twenty-four
hours after infection, relative luciferase activity was measured. Data shown are mean ± SD of three independent experiments with each condition performed in
duplicate. (E,F) ME-180 cells were transfected with or without pGL3-TLR9 were infected with ascending doses of HSV-2 for 24 h (E) or with 0.5 MOI HSV-2 for
ascending infection time periods (F). After incubation, relative luciferase activity was measured. Data shown are mean ± SD of three independent experiments with
each condition performed in duplicate. (G–J) ME-180 cells were infected with or without ascending doses of HSV-2 for 24 h (G,I) or infected with 0.5 MOI HSV-2 for
ascending infection time periods (H,J). After incubation, TLR9 mRNA level (G,H) and protein level (I,J) were determined by RT-PCR (G,H) and Western blot (I,J),
respectively. For RT-PCR results, data shown are mean ± SD of three independent experiments with each condition performed in duplicate. For Western blot results,
one representative experiment out of three is shown. ns, statistically not significant; *p < 0.05; **p < 0.01; ***p < 0.001.
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FIGURE 2 | HSV-2-induced TLR9 expression is viral replication-dependent. ME-180 cells were transfected with or without pGL3-TLR9 and infected with HSV-2 (A–C)
or treated with CpG or GpC ODNs (D–F). Twenty-four hours after infection or treatment, relative luciferase activity (A,D), relative TLR9 mRNA level (B,E), and TLR9
protein level (C–F) were determined by dual luciferase activity assay (A,D), RT-PCR (B,E), and Western blot (C,F), respectively. For luciferase assay and RT-PCR, data
shown are mean ± SD of three independent experiments with each condition performed in duplicate. For Western blot results, one representative experiment out of
three is shown. ns, statistically not significant; **p < 0.01; ***p < 0.001.
shown in Figure 5B, SP1 overexpression significantly enhanced
TLR9 promoter activity. The essential role of SP1 in HSV-2-
induced TLR9 transactivation was also confirmed by siRNA
interference of SP1. Luciferase reporter gene assay showed that
HSV-2-induced transactivation of TLR9 promoter was largely
impaired when SP1 was knocked down by siRNAs (Figure 5C).
Western blot analysis showed consistent results, revealing a
SP1-dependent TLR9 expression under the condition of HSV-
2 infection (Figure 5D). In order to regulate promoter activity,
transcription factors need to translocate from the cytoplasm to
the nucleus. We next investigated whether HSV-2 infection also
enhanced SP1 nuclear translocation. As shown in Figure 5E,
a near full nuclear translocation of SP1 was observed when
cells were infected with HSV-2. In addition, upon HSV-2
infection, an increased SP1 phosphorylation level (top band)
(20) was seen in the nuclear fraction, indicating that HSV-
2 infection also enhanced SP1 phosphorylation (Figure 5E).
Taken together, these data here indicate that HSV-2 infection
induces TLR9 expression via promoting SP1 binding to
TLR9 promoter.
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FIGURE 3 | HSV-2-induced TLR9 expression does not activate TLR9 signaling pathway. (A) ME-180 cells were transfected with pGL3-TLR9 or pGL3-IL-6 and
infected with 0.5 MOI HSV-2 for 24 h. After incubation, relative luciferase activity was measured. Data shown are mean ± SD of three independent experiments with
each condition performed in duplicate. (B) ME-180 cells or PBMCs were infected with or without HSV-2 or treated with or without CpG or GpC ODNs for 24 h. After
incubation, IL-6 concentration in the cell culture supernatants were measured by ELISA. Data shown are mean ± SD of three independent experiments with each
condition performed in duplicate. ns, statistically not significant; **p < 0.01; ***p < 0.001. (C) ME-180 cells were either mock-infected, or infected with UV-HSV-2,
HSV-2 or transfected with pTLR9. Twenty-four hours later, cells were lysed and immunoprecipitation was performed with anti-MyD88 antibody and the presence of
TLR9 and MyD88 in the pulldown was detected by Western blot. One representative experiment out of three is shown.
HSV-2 Induces TLR9 Expression by
Activating JNK Signaling Pathway
To determine which signaling pathway(s) was involved in HSV-
2-induced TLR9 upregulation, inhibitors targeting TBK1/IKKε
(BX795), IκBα (BAY11-7082), JNK (SP600125), and p38/MAPK
(SB203580) were used. As shown in Figure 6A, only the
addition of SP600125 significantly reduced the luciferase activity,
indicating a JNK-dependent signaling pathway. To further
confirm these findings, signaling inhibition assay was repeated
in both ME-180 and primary foreskin epithelial cells where TLR9
expression was determined by Western blot. In consistent with
the luciferase reporter gene assay, SP600125, but not SB203580
could significantly decrease TLR9 expression in both ME-180
(Figure 6B) and foreskin epithelial cells (Figure 6C).
We next determined the impact of HSV-2 infection on the
activation of JNK signaling pathway. As shown in Figure 6D,
HSV-2 infection did not show apparent impact on JNK
expression, but significantly increased its phosphorylation
level. The impact of inhibiting JNK signaling pathway on
SP1 phosphorylation and nuclear translocation was also
investigated. As shown in Figure 6E, SP600125, but not
SB203580, significantly decreased SP1 nuclear translocation.
Furthermore, upon SP600125 treatment, SP1 phosphorylation
level was also considerably decreased in the nucleus.
Collectively, our study has revealed that replicative, but
not UV-inactivated HSV-2 induces TLR9 expression in human
genital epithelial cells, and this induction is through promoting
SP1 binding to TLR9 promoter via JNK signaling pathway.
DISCUSSION
It is known that HSV-2 is recognized by TLR2/3/9 signaling
pathway in immunocompetent cells like DCs, NK cells
and macrophages, leading to the production of antiviral
inflammatory cytokines, such as type I IFNs, IL-6, and IL-12.
However, little attention has been paid to the interaction between
HSV-2 and TLRs in genital epithelial cells. In the current study,
we reveal that HSV-2 infection triggers TLR9 expression in
both human genital epithelial cell lines and primary cells. We
demonstrate that HSV-2-induced TLR9 expression is mediated
by promoting SP1 binding to TLR9 promoter via JNK signaling
pathway. Since TLR9 expression is mainly manifested at 24 h
post infection, it is possible that HSV-2 drives a response which
subsequently activates TLR9 promoter. Although it remains to
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FIGURE 4 | SP1 binding site on TLR9 promoter is involved in HSV-2-induced TLR9 transactivation. (A) ME-180 cells were transfected with reporter plasmids with 5′
serial deletions within the TLR9 promoter region and infected with or without 0.5 MOI HSV-2 for 24 h. After incubation, relative luciferase activity was measured. Data
shown are mean ± SD of three independent experiments with each condition performed in duplicate. (B) TLR9 promoter sequence was analyzed by Gene2promoter
software and the predicted transcription binding sites were shown. (C) ME-180 cells were transfected with reporter plasmids with or without mutations within the
TLR9 promoter region and infected with or without 0.5 MOI HSV-2 for 24 h. After incubation, relative luciferase activity was measured. Data shown are mean ± SD of
three independent experiments with each condition performed in duplicate. ns, statistically not significant; ***p < 0.001.
be determined whether a secondary response is involved in the
HSV-2-induced TLR9 expression, we can largely rule out the
involvement of HSV-2-induced cytokines in the process, as we
found that cytokines in the viral stock did not activate TLR9
promoter. Given that HSV-2 in our current study was propagated
in ME-180, the cell line also used for the subsequent infection
experiments, the cytokine composition induced in the infection
experiments would be similar to that in the viral stock and
unlikely to impact TLR9 expression.
TLRs recognize pathogens and activate downstream
signaling members to initiate innate immune responses. In
general, increased TLR expression can increase pathogen
recognition, which leads to enhanced immune response (21). For
instance, upregulation of TLR4 expression by IL-27 enhances
proinflammatory cytokine production in human monocytes
(22). GM-CSF-promoted expression of TLR3 and TLR7 increases
the release of IL-13 and IL-6 in mast cells (23). Of interest, in
our current study, although a significant increase of TLR9
expression was observed when epithelial cells were infected with
HSV-2, we did not observe an apparently increased activation
of TLR9 signaling pathway. In contrast, TLR9 overexpression
in the absence of HSV-2 did trigger the activation of the
signaling pathway in genital epithelial cells, showing that TLR9
overexpression in ME-180 cells activated the TLR9 signaling,
which resulted in enhanced IL-6 secretion in the cell culture
(Figure S2). Moreover, we found that genital epithelial cells with
ectopic overexpression of TLR9 were resistant to HSV-2 infection
(Figure S3), indicating a TLR9 mediated anti-HSV-2 capability
in the genital epithelial cells. Nevertheless, HSV-2-induced
TLR9 expression appeared not to trigger the activation of the
downstream signaling pathway, suggesting that HSV-2 may have
evolved a mechanism to antagonize the TLR9 signaling pathway.
We found that HSV-2-induced TLR9 expression is HSV-
2 replication-dependent and CpG-independent, indicating that
TLR9 expression is induced by HSV-2 infection rather than the
CpGmotifs within the viral genome. It has been shown that TLR9
can antagonize affinity maturation by preventing B cells from
antigen capture and presentation (24). TLR9 was also reported to
negatively modulate antifungal functions in macrophages (25).
Although further investigation is required, it is probable that
HSV-2 increases TLR9 expression as a mechanism to interrupt
host adaptive immune response. It is known that HSV-2 progeny
virus packaging happens in the Golgi apparatus which uses
intracellular membrane system for virus release (26). During this
process, the virus usually adopts cellular functions and pathways
to facilitate its release by specifically interacting with host cell
lipids and proteins (27). Since TLR9 is mainly present in the
intracellular vesicles and circulates within the membrane system
(28, 29), future study is warranted to determine whether HSV-2
can hijack TLR9 to enhance virus transportation.
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FIGURE 5 | HSV-2 infection promotes SP1 phosphorylation and nuclear translocation. (A) ME-180 cells were infected with or without 0.5 MOI HSV-2 for 24 h and
chromatin immunoprecipitation assay was performed using anti-SP1 antibody and control IgG. The amplification of input samples was also shown. One representative
experiment out of three is shown. (B) ME-180 cells co-transfected with pGL3-TLR9 and pcDNA3.1-SP1 or pcDNA3.1 for 24 h, and then relative luciferase activity was
measured. Data shown are mean ± SD of three independent experiments with each condition performed in duplicate. (C,D) ME-180 cells were sequentially
transfected with SP1 siRNAs or control siRNA (C,D) and pGL3-TLR9 (C), and then infected with HSV-2. Twenty-four hours after infection, relative luciferase activity
(C) and TLR9 and SP1 expression were determined by dual luciferase assay (C) and Western blot (D), respectively. For luciferase assay and RT-PCR, data shown are
mean ± SD of three independent experiments with each condition performed in duplicate. For Western blot results, one representative experiment out of three is
shown. (E) ME-180 cells were infected with or without HSV-2 for 24 h. Cell cytoplasmic and nuclear fractions were isolated, and SP1 expression was determined by
Western blot. One representative experiment out of three is shown. ns, statistically not significant; *p < 0.05; **p < 0.01.
The impact of HSV-2 infection on TLR9 activation in
pDCs has been previously described, the findings of which
are quite different from those observed in our current study
using genital epithelial cells as models. In pDCs, both live
and UV-inactivated HSV-2 induced IFN-α production by
activating TLR9/MyD88 signaling pathway (13), whereas in
genital epithelial cells, only live HSV-2 upregulated TLR9
expression and neither live nor UV-inactivated HSV-2 activated
TLR9 signaling pathway. Such discrepancy may be attributed to
differences in cell targets. DCs as immunocompetent antigen-
presenting cells have high level of TLR9 expression (30),
and upon HSV-2 infection, TLR9 can be activated by viral
dsDNA before viral antagonism takes place. In contrast to that
in immune cells, TLR9 expression in epithelial cells is less
ubiquitous (30). We observed that, prior to HSV-2 infection,
TLR9 expression was hardly detectable in genital epithelial
cells at both mRNA and protein levels. The lack of TLR9
expression may explain why UV-inactivated HSV-2 or CpG
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FIGURE 6 | JNK signaling pathway is involved in HSV-2-induced TLR9 expression. (A) ME-180 cells were transfected with pGL3-TLR9, infected with HSV-2 and
treated with various signaling pathway inhibitors. Twenty-four hours after treatment, relative luciferase activity was measured. Data shown are mean ± SD of three
independent experiments with each condition performed in duplicate. (B–E) ME-180 (B,D,E) and primary foreskin epithelial cells (C) were infected with HSV-2 and
treated with various signaling pathway inhibitors. Twenty-four hours later, TLR9 (B,C) and JNK and p-JNK (D) expression were determined by Western blot.
(E) Cytoplasmic and nuclear fractions were isolated and SP1 expression was determined by Western blot. One representative experiment out of three is shown.
ODN was unable to activate TLR9 signaling pathway in genital
epithelial cells.
It is not yet clear whether HSV-2 infection upregulated TLR9
expression is important to viral replication or simply a byproduct
during its replication. However, the upregulated TLR9 may
shed light on the understanding of HSV-2 enhanced HIV-1
infection. It has been reported that TLR9 can transactivate HIV-
1 LTR and initiate viral replication (31, 32). In addition, TLR9
polymorphism is related to HIV-1 progression (33, 34). In a
separate study, we have also observed that replicative HSV-2 but
not UV-treated HSV-2 activates HIV-1 LTR and this activation is
sensitive to TLR9 siRNA treatment (unpublished data). Although
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further investigations are needed, these findings imply that HSV-
2 may promote HIV-1 replication in a TLR9-dependent manner.
In conclusion, our study has revealed that replicative,
but not UV-inactivated HSV-2 induces TLR9 expression
in genital epithelial cells, and that such induction is
through promoting SP1 binding to TLR9 promoter via JNK
signaling pathway.
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